The Japanese healthcare authorities have decided to improve reimbursement for intermittent catheters. This represents a breakthrough in the Japanese market for Coloplast, who will have an easier time offering the newest and best catheters to people living with incontinence in Japan.
“We already have a solid market share when it comes to our ostomy business in the Japanese market. With the new reimbursement rules in place, we see improving business opportunities for our continence business and we will surely benefit from them,” says Lars Rasmussen, CEO of Coloplast.
Coloplast has had a subsidiary in Japan for 28 years and Lars Rasmussen sees great potential for growth in the country going forward.
“There are close to 100,000 people in Japan living with incontinence who need a catheter and they will now have access to better and more modern products. That is very positive,” says Lars Rasmussen.
Japan generally has an advanced and very modern healthcare system, and with improved reimbursement in place, the monthly supplement per catheter user will increase with more than 50 percent.
This means better access to improved products and is a result of, among other things, Coloplast’s contribution of health economic data to the Japanese authorities.
Coloplast products are sold in more than 130 countries worldwide and Japan is an important market in the company’s future growth plans.
Contact
Media Relations
Maria Lindeberg
Senior Manager, Media Relations
Tel. +45 49113095
dkmalg@coloplast.com
Investor Relations
Ian S.E. Christensen
Vice President, Investor Relations
Tel. +45 4911 1800/+45 4911 1301
dkisec@coloplast.com
